Dynavax gains on Heplisav update

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $0.41 (17%) to $2.84 on Thursday after FDA said the company demonstrated the clinical consistency of three consecutively manufactured lots of its HBV vaccine candidate Heplisav. The company now plans to submit a BLA to the agency by year end. ...